Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for BridgeBio Oncology Therapeutics's Equity-to-Asset or its related term are showing as below:
BBOT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -19.46 Med: -0.11 Max: 0.92
Current: 0.86
During the past 3 years, the highest Equity to Asset Ratio of BridgeBio Oncology Therapeutics was 0.92. The lowest was -19.46. And the median was -0.11.
BBOT's Equity-to-Asset is ranked better than 75% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs BBOT: 0.86
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BridgeBio Oncology Therapeutics Equity-to-Asset Related Terms
BridgeBio Oncology Therapeutics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BBOT vs CTMX, GYRE, TECX: Equity-to-Asset Comparison
For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Oncology Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BridgeBio Oncology Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Oncology Therapeutics (BBOT) has a Equity-to-Asset of 0.86 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BridgeBio Oncology Therapeutics and its competitors. According to the industry distribution chart, BridgeBio Oncology Therapeutics ranks #353 out of 1412 companies in the Biotechnology industry, placing it in the top 25%.
Is BridgeBio Oncology Therapeutics' Equity-to-Asset too high?
BridgeBio Oncology Therapeutics' current Equity-to-Asset is 0.86. The Biotechnology industry median Equity-to-Asset is 0.69. BridgeBio Oncology Therapeutics' value of 0.86 is 24.6% above this industry median. Based on the distribution chart, BridgeBio Oncology Therapeutics ranks #353 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Equity-to-Asset compare to CTMX and GYRE?
According to the Biotechnology industry distribution chart, BridgeBio Oncology Therapeutics ranks #353 out of 1412 companies for Equity-to-Asset. This places BridgeBio Oncology Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.69. BridgeBio Oncology Therapeutics' value of 0.86 is 24.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Oncology Therapeutics's current Equity-to-Asset of 0.86 is 24.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BridgeBio Oncology Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Oncology Therapeutics's current Equity-to-Asset is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Equity-to-Asset of 0.86. The current Equity-to-Asset is 0.86 and 24.6% above the Biotechnology industry median of 0.69. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Equity-to-Asset is 0.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score
Get the complete analysis for BBOT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBOT has been successfully added to your 
